New York, United States
Prevail Therapeutics, founded in 2017, is a pioneering biotech company focused on developing novel gene therapies aimed at addressing the root genetic causes of Parkinson’s disease and other neurodegenerative disorders. Their mission is to convert recent advances in human genetics and gene therapy technology into transformative medicines that slow or halt neurodegeneration.
The company's strategy hinges on a precision medicine approach, targeting patient groups with critical unmet needs where current treatments fail to alter disease progression. In January 2021, Prevail was acquired by Eli Lilly and Company for $1.04B, becoming its wholly-owned subsidiary. This acquisition underscores Eli Lilly’s commitment to expanding its presence in the gene therapy domain.
Operating from the Alexandria Center for Life Science in New York City, Prevail is composed of a team committed to leveraging innovation in the fight against neurodegenerative diseases, promoting values like collaboration, integrity, and agility in its operations.
